LYSARC,
Academic partner
of Lymphoma
Clinical Research

23rd Congress of EHA: Results of the RELEVANCE Clinical Study Selected in the Presidential Symposium!

22 May 2018,

The 23rd annual congress of the European Hematology Association (EHA) will take place from 14 to 17 June 2018 in Stockholm (Sweeden). The abstract “RELEVANCE: Phase III efficacy and safety of lenalidomide plus rituximab (R2) versus rituximab plus chemotherapy, followed by rituximab, in previously untreated follicular lymphoma”, submitted on the RELEVANCE study, conducted by LYSA-LYSARC was selected in the presidential symposium with five other communications! It will be presented by Franck Morschhauser from Hospital University Centre of Lille, France.

For more information:https://learningcenter.ehaweb.org/eha/2018/stockholm/215924/frank.morschhauser.relevance.phase.iii.efficacy.and.safety.study.of.html?f=menu=6*ce_id=1346*ces_id=15214*media=3*mar